Evidence map›Paper›PMID 30375485›Full record

Trial reportScientific reports2018

Neuromodulation treats Chikungunya arthralgia: a randomized controlled trial.

Edson Silva-Filho, Alexandre H Okano, Edgard Morya, Jessica Albuquerque, Enio Cacho, Gozde Unal, Marom Bikson, Rodrigo Pegado

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Non-Pharmacological Therapies for Post-Viral Syndromes, Including Long COVID: A Systematic Review.International journal of environmental research and public health · 2023
    Pooled it
  4. Pooled it
  5. Review
  6. Review
  7. Article
  8. [Evidence map of chikungunya treatmentsMapa de la evidencia sobre el tratamiento del chikunguña].Revista panamericana de salud publica = Pan American journal of public health · 2024
    Article
  9. Chikungunya fever.Nature reviews. Disease primers · 2023
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Edson Silva-FilhoPostgraduate Program in Rehabilitation Sciences, Federal University of Rio Grande do Norte, Santa Cruz, Brazil.
Alexandre H OkanoCenter of Mathematics, Computation and Cognition, Universidade Federal do ABC, São Bernardo, São Paulo, Brazil.ORCID http://orcid.org/0000-0002-8995-1392
Edgard MoryaEdmond and Lily Safra International Institute of Neuroscience, Santos Dumont Institute, Macaiba, Brazil.ORCID http://orcid.org/0000-0003-0954-5317
Jessica AlbuquerqueDepartment of Social Psychology, Federal University of Paraíba, João Pessoa, Brazil.
Enio CachoPostgraduate Program in Rehabilitation Sciences, Federal University of Rio Grande do Norte, Santa Cruz, Brazil.
Gozde UnalDepartment of Biomedical Engineering, The City College of The City University of New York, New York, USA.
Marom BiksonDepartment of Biomedical Engineering, The City College of The City University of New York, New York, USA.
Rodrigo PegadoPostgraduate Program in Rehabilitation Sciences, Federal University of Rio Grande do Norte, Santa Cruz, Brazil. rodrigopegado@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Chikungunya (CHIK) virus is epidemic in Brazil, with 170,000 cases in the first half of 2016. More than 60% of patients present relapsing and remitting chronic arthralgia with debilitating pain lasting years. There are no specific therapeutic agents to treat and rehabilitee infected persons with CHIK. Persistent pain can lead to incapacitation, requiring long-term pharmacological treatment. Advances in non-pharmacological treatments are necessary to promote pain relief without side effects and to restore functionality. Clinical trials indicate transcranial direct current stimulation (tDCS) can treat a broad range of chronic pain disorders, including diffuse neuromuscular pain and arthralgia. Here, we demonstrate that the tDCS across the primary motor cortex significantly reduces pain in the chronic phase of CHIK. High-resolution computational model was created to analyze the cortical electric field generated during tDCS and a diffuse and clustered brain current flow including M1 ipsilateral and contralateral, left DLPFC, nucleus accumbens, and cingulate was found. Our findings suggest tDCS could be an effective, inexpensive and deployable therapy to areas lacking resources with a significant number of patients with chronic CHIK persistent pain.

Indexed as

Pain ManagementAdultAgedArthralgiaChikungunya FeverChronic PainFemaleHumansImage Processing, Computer-AssistedImaging, Three-DimensionalMaleMiddle AgedNeurotransmitter AgentsPain MeasurementTranscranial Direct Current StimulationTranscranial Magnetic StimulationNeurotransmitter Agents

Identifiers

PMID30375485
PMCPMC6207669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.